A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma

References

• Parikh RR, Grossbard ML, Green BL, et al. Disparities in survival by insurance status in patients with Hodgkin lymphoma. Cancer. 2015;121(19):3515–3524.
   PubMed Web of Science ®Google Scholar
• Koshy M, Fairchild A, Son CH, et al. Improved survival time trends in Hodgkin’s lymphoma. Cancer Med. 2016;5(6):997–1003.
   PubMed Web of Science ®Google Scholar
• Major A, Jackson MW, Smith DE, et al. Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. Leuk Lymphoma. 2019;60(5):1234–1243.
   PubMed Web of Science ®Google Scholar
• Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692–695.
   PubMed Web of Science ®Google Scholar
• Klimm B, Eich HT, Haverkamp H, et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol. 2007;18(2):357–363.
   PubMed Web of Science ®Google Scholar
• Engert A, Ballova V, Haverkamp H, et al. Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s Study Group. J Clin Oncol. 2005;23(22):5052–5060.
   PubMed Web of Science ®Google Scholar
• Stark GL, Wood KM, Jack F, et al.; on behalf of the Northern Region Lymphoma Group. Hodgkin’s disease in the elderly: a population-based study. Br J Haematol. 2002;119(2):432–440.
   PubMed Web of Science ®Google Scholar
• Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park, N.Y.). 2008;22(12):1369–1379.
   PubMed Web of Science ®Google Scholar
• Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179–184.
   PubMed Web of Science ®Google Scholar
• Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical hodgkin lymphoma. J Clin Oncol. 2018;36(30):3015–3022.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL. Blood. 2017;130(26):2829–2837.
   PubMed Web of Science ®Google Scholar
• Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118(24):6292–6298.
   PubMed Web of Science ®Google Scholar
• Boll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127(18):2189–2192.
   PubMed Web of Science ®Google Scholar
• Boll B, Gorgen H. The treatment of older Hodgkin lymphoma patients. Br J Haematol. 2019;184(1):82–92.
   PubMed Web of Science ®Google Scholar
• Allen PB, Winter JN. Controversies in the approach to initial therapy of Hodgkin Lymphoma. Curr Oncol Rep. 2019;21(5):39.
   PubMed Web of Science ®Google Scholar
• Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16(1):124–131.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–3739.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294.
   PubMed Web of Science ®Google Scholar
• Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3rd ed. New York: John Wiley & Sons; 2003.
   Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798–2804.
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344.
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Fanale MA, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 study. Blood. 2017;130(Suppl 1):651.
   Google Scholar
• Eichenauer DA, Plutschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18(12):1680–1687.
   PubMed Web of Science ®Google Scholar
• Kumar A, Casulo C, Yahalom J, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016;128(11):1458–1464.
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–1356.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Schiano de Colella J, Viotti J, et al. Brentuximab-vedotin and bendamustine is a feasible and effective drug combination as first-line treatment of hodgkin lymphoma in the elderly (HALO trial). Hematol Oncol. 2019;37(S2):292–293.
   Google Scholar
• Evens AM, Connors JM, Younes A, et al. Older patients (pts) with previously untreated classical Hodgkin lymphoma (cHL): a detailed analysis from the phase 3 ECHELON-1 study. Blood. 2018;132(Supplement 1):1618–1618.
   PubMedGoogle Scholar
• Boell B, Fosså A, Goergen H, et al. B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in older patients with advanced-stage hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG). Blood. 2018;132(Supplement 1):926–926.
   Google Scholar
• Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76–86.
   PubMed Web of Science ®Google Scholar
• Halbsguth TV, Nogova L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010;116(12):2026–2032.
   PubMed Web of Science ®Google Scholar
• Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013;31(12):1522–1529.
   PubMed Web of Science ®Google Scholar
• Zallio F, Tamiazzo S, Monagheddu C, et al. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol. 2016;172(6):879–888.
   PubMed Web of Science ®Google Scholar
• Boll B, Plutschow A, Burkle C, et al. Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. Br J Haematol. 2019;185(1):42–52.
   PubMed Web of Science ®Google Scholar
• Evens AM, Hong F, Gordon LI, et al. Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): analysis from the phase III randomized U.S. Intergroup Trial E2496. J Clin Oncol. 2011;29(15_suppl):8035–8035.
   Web of Science ®Google Scholar
• Gallamini A, Bijou F, Viotti J, et al. Brentuximab-vedotin and bendamustine is a feasible and effective drug combination as first-line treatment of Hodgkin lymphoma in the elderly (HALO trial). Hematol Oncol. 2017;35(S2):170–170.
   Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566.
   PubMed Web of Science ®Google Scholar